Introduction: A recent clinical trial underscored the importance of repeated minimal residual disease (MRD) monitoring by RQ-PCR in Mantle Cell Lymphoma (MCL), a disease with initially high response rates but both early and late relapses [Ferrero Blood 2022]. However, MRD kinetics are complex, posing interpretation and clinical application challenges.
Unraveling MRD Dynamics to Enhance Outcome Prediction in Mantle Cell Lymphoma—Insights from the Fondazione Italiana Linfomi MCL0208 Clinical Trial / Cordero, F.; Ferrero, S.; Pernice, S.; Genuardi, E.; Volpatto, D.; Sirovich, R.; Civita, A. M.; Evangelista, A.; Ragaini, S.; Di Rocco, A.; Re, A.; Stefanoni, V.; Cavallo, F.; Boccomini, C.; Balzarotti, M.; Zilioli, V. R.; Gomes Da Silva, M.; Arcaini, L.; Tosi, P.; Zaccaria, G. M.; Tortarolo, D.; Hoster, E.; Pott, C.; Macintyre, E.; Dreyling, M.; Ladetto, M.. - In: HEMATOLOGICAL ONCOLOGY. - ISSN 0278-0232. - STAMPA. - 43:S3(2025). [10.1002/hon.70096_532]
Unraveling MRD Dynamics to Enhance Outcome Prediction in Mantle Cell Lymphoma—Insights from the Fondazione Italiana Linfomi MCL0208 Clinical Trial
Zaccaria, G. M.;
2025
Abstract
Introduction: A recent clinical trial underscored the importance of repeated minimal residual disease (MRD) monitoring by RQ-PCR in Mantle Cell Lymphoma (MCL), a disease with initially high response rates but both early and late relapses [Ferrero Blood 2022]. However, MRD kinetics are complex, posing interpretation and clinical application challenges.| File | Dimensione | Formato | |
|---|---|---|---|
|
2025_Unraveling_MRD_Dynamics_to_Enhance_Outcome_Prediction_in_Mantle_Cell_Lymphoma—Insights_pdfeditoriale.pdf
solo gestori catalogo
Tipologia:
Versione editoriale
Licenza:
Tutti i diritti riservati
Dimensione
453.86 kB
Formato
Adobe PDF
|
453.86 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
